{"filing":{"accession_number":"0001104659-26-077790","cik":"0001006281","ticker":"PLX","company_name":"Protalix BioTherapeutics, Inc.","form":"8-K","filing_date":"2026-06-25","report_date":null,"primary_document":"plx-20260625x8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1006281/000110465926077790/plx-20260625x8k.htm"},"events":[{"id":13939,"run_id":12391,"accession_number":"0001104659-26-077790","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"This Item 5.07 disclosure reports the results of Protalix's 2026 Annual Meeting of Stockholders held on June 25, 2026, including voting outcomes on four proposals: election of eight directors, advisory approval of named executive officer compensation, approval of an amended stock incentive plan increasing available shares by 3.5 million, and ratification of the independent auditor (Kesselman \u0026 Kesselman/PwC). The detailed vote tallies for each proposal are provided, which is the core content of a shareholder vote results disclosure.","company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","filing_date":"2026-06-25","form":"8-K","submitted_at":null,"items":[{"id":11227,"accession_number":"0001104659-26-077790","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 disclosure reports the results of Protalix's 2026 Annual Meeting of Stockholders held on June 25, 2026, including voting outcomes on four proposals: election of eight directors, advisory approval of named executive officer compensation, approval of an amended stock incentive plan increasing available shares by 3.5 million, and ratification of the independent auditor (Kesselman \u0026 Kesselman/PwC). The detailed vote tallies for each proposal are provided, which is the core content of a shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:31:45.488440+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":11227,"accession_number":"0001104659-26-077790","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This Item 5.07 disclosure reports the results of Protalix's 2026 Annual Meeting of Stockholders held on June 25, 2026, including voting outcomes on four proposals: election of eight directors, advisory approval of named executive officer compensation, approval of an amended stock incentive plan increasing available shares by 3.5 million, and ratification of the independent auditor (Kesselman \u0026 Kesselman/PwC). The detailed vote tallies for each proposal are provided, which is the core content of a shareholder vote results disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-25T20:31:45.488440+00:00","company_name":"Protalix BioTherapeutics, Inc.","ticker":"PLX","filing_date":"2026-06-25"}]}